ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
ABVC BioPharma Inc

ABVC BioPharma Inc (ABVC)

1.31
0.11
(9.17%)
Closed March 29 04:00PM
1.28
-0.03
(-2.29%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.28
Bid
1.25
Ask
1.33
Volume
678,552
1.1601 Day's Range 1.30
0.6739 52 Week Range 9.60
Market Cap
Previous Close
1.20
Open
1.17
Last Trade Time
Financial Volume
$ 842,368
VWAP
1.2414
Average Volume (3m)
846,034
Shares Outstanding
10,560,421
Dividend Yield
-
PE Ratio
-0.83
Earnings Per Share (EPS)
-1.56
Revenue
970k
Net Profit
-16.42M

About ABVC BioPharma Inc

ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved heal... ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Reno, Nevada, USA
Founded
1970
ABVC BioPharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABVC. The last closing price for ABVC BioPharma was $1.20. Over the last year, ABVC BioPharma shares have traded in a share price range of $ 0.6739 to $ 9.60.

ABVC BioPharma currently has 10,560,421 shares outstanding. The market capitalization of ABVC BioPharma is $13.62 million. ABVC BioPharma has a price to earnings ratio (PE ratio) of -0.83.

ABVC Latest News

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars

FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions...

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions...

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that...

Form 8-K/A - Current report: [Amend]

true Amendment no. 1 to Form 8-k 0001173313 0001173313 2024-01-16 2024-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares...

Form 8-K/A - Current report: [Amend]

true Amendment no. 1 to Form 8-k 0001173313 0001173313 2023-11-20 2023-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares...

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

As filed with the Securities and Exchange Commission on February 16, 2024 Registration No. 333-276500 Registration No. 333-271416     SECURITIES AND EXCHANGE COMMISSION Washington...

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

FREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G       Under the Securities...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.218.51851851851.081.451.0358209121.27415698CS
40.086.666666666671.21.451.0315245571.27015146CS
12-0.57-30.81081081081.851.851.038460341.31907477CS
260.2524.27184466021.033.350.673924127731.53712465CS
52-4.72-78.666666666769.60.673914347572.0133156CS
156-31.92-96.144578313333.2116.8830.6739101033818.58117356CS
260-31.92-96.144578313333.2116.8830.6739101033818.58117356CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

ABVC Discussion

View Posts
Welsh_Dragon Welsh_Dragon 2 days ago
One day ok
👍️0
Invest-in-America Invest-in-America 2 days ago
ABVC: Heck, Boss, just about EXACTLY what I myself lost today on my @KULR gambit!! (I didn't pay enough attention to their PR's clever characterization of their new deal with glorious Lockheed Martin --- to wit, where they said it is a "six figure" contract, which was likely a paltry $200,000 bucks!! Heck, you yourself might play for more than THAT at a private POKER PARTY at Myrtle Beach!!!)
👍️0
TheFinalCD TheFinalCD 3 days ago
lost money on this turd today


-$500
👍️0
Invest-in-America Invest-in-America 3 days ago
ABVC: It was good news, & it SHOULD be doing well.
👍️0
timetomakemoney timetomakemoney 3 days ago
Well let's see if insiders start buying shares.
👍️0
Invest-in-America Invest-in-America 3 days ago
ABVC: Shocking!!! That this is NOT up by at least 200% by now, behind THAT kind of news!! (What a frickin' CRAPS-SHOOT Wall Street has become; makes the old OTC of years ago look like a relatively STABLE 'gambling' system.)

PS: I myself jumped-on the MONSTER news from KULR early this morning, and THAT TOO is being FLUSHED down the toilet!!!
👍️0
TheFinalCD TheFinalCD 3 days ago
GOT LINK?
👍️0
stock1ace1 stock1ace1 3 days ago
This is a chinese scam stock twits exposed this turd be cautious trading this
👍️0
TheFinalCD TheFinalCD 3 days ago
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
https://www.globenewswire.com/news-release/2024/03/26/2852346/0/en/ABVC-BioPharma-Entered-into-a-Global-Licensing-Deal-of-Vitargus-with-Licensing-Income-of-33-5M-and-Royalties-up-to-60M.html
👍️0
TheFinalCD TheFinalCD 3 days ago
$ABVC IN 1.54 https://www.globenewswire.com/news-release/2024/03/26/2852346/0/en/ABVC-BioPharma-Entered-into-a-Global-Licensing-Deal-of-Vitargus-with-Licensing-Income-of-33-5M-and-Royalties-up-to-60M.html
👍️0
Awl416 Awl416 3 days ago
Oink oink

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
👍️0
timetomakemoney timetomakemoney 1 week ago
Yesterday PR was nothing new. Not sure why they decided to do a PR.
👍️0
Monksdream Monksdream 2 weeks ago
ABVC under $2
👍️0
timetomakemoney timetomakemoney 3 weeks ago
Yes... Slowly adding shares at these prices.
👍️0
crudeoil24 crudeoil24 3 weeks ago
Agree! Especially if company is generating a nice revenue package.
👍️0
timetomakemoney timetomakemoney 3 weeks ago
The TA chart looks like a breakout. PPS has Consolidationed and now climbing upward. I sense news coming.
👍️0
Monksdream Monksdream 1 month ago
ABVC under $2
👍️0
crudeoil24 crudeoil24 1 month ago
Still holding shares. Patience will pay off . Let's go ABVC !
👍️0
TheFinalCD TheFinalCD 1 month ago
$ABVC NEWS LISC AGREEMENT NEWS
$ABVC 08:30 on Feb. 15 2024

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues— NuntioBot (@NuntioBot) February 15, 2024
https://finviz.com/quote.ashx?t=ABVC&ty=c&ta=1&p=d
👍️0
Beauneedsbiscuits Beauneedsbiscuits 2 months ago
Wrong again..like usual!!! Someday you'll get something right. .like staying out of the market!!
👍️0
kbaz kbaz 3 months ago
It Better Hurry!!!!
👍️0
crudeoil24 crudeoil24 3 months ago
$2.00+ this week. ABVC is a great $$$$$ opportunity!
👍️0
kbaz kbaz 3 months ago
No Doubt this is wanting to remain above $2.00/$3.00 Seems like a lot of unnatural force to hold this Sub $2.... Until then expect days/weeks/months of Rips!!!!!
👍️0
stock1ace1 stock1ace1 3 months ago
Same news was back on nov 17th seems odd ?

https://www.pharmaceutical-technology.com/news/aibtl-signs-667m-licensing-deal-for-abvcs-cns-drug/?cf-view
👍️0
kbaz kbaz 3 months ago
HAHAHAHA!!! I'm just a little guy who goes in/out. I be watchin' my points... I don't expect $25 by Friday..... Christmas jus' came and went!
👍️0
Invest-in-America Invest-in-America 3 months ago
Hope ya GET that $25 stock price by FRIDAY of this week, Dude!!
👍️0
kbaz kbaz 3 months ago
Ain't got shid to do with anything but the fact that almost $200 million churned today on a tiny little float. And the Chart is still holding pretty steady. Setting up for a Multi Day/Week/Month long story that we got a sneak peak end of Oct'23 and Definitely opportunity to grab at $1.0's until couple days ago..... Stair Step to Glory!!!!!! I predict $25's.... in '24!!!
👍️0
Invest-in-America Invest-in-America 3 months ago
ABVC: Indeed, Dude!!! For the proverbial 'bottom line' about ABVC, all one has to do is see the film-clip (below) of what my BROKER here in San Diego said to ME just before I grabbed this baloney sandwich 'company' early this morning!!

👍️0
kbaz kbaz 3 months ago
The Market is looking to painfully be figuring out what has Happened here!!!!! The Painful Catching up is rewarding in the Message Boards. HAHAHAHAHAHAHA!

This ain't no Coffee and Donuts wannabe Starbucks POS!!!!!!! This got room to the upside overnight.... Could be $25.00 with the blink of an eye!!!!! FLIPPITY FLIP FLIP FLIP......

👍️0
Invest-in-America Invest-in-America 3 months ago
ABVC: WRONG, Bro!!! See ME, below, in the TRUE "gift that keeps giving", Homeboy!! (I.e., my new Peloton, "Hot-Blonde-CHICKS-Tub"!!!)

👍️0
Invest-in-America Invest-in-America 3 months ago
ABVC: Old George J. would have got-up-in-my-face with something like, "What you talkin' about, CRACKER!!??"
👍️0
Invest-in-America Invest-in-America 3 months ago
ABVC: Imagine if their 'news' PR today revealed a $460-mil. (real) CASH DEAL for their Health Care stuff --- from the likes of MERCK, etc.!!!! If so, this would be at least a 5-bagger by now!!!
👍️0
stock1ace1 stock1ace1 3 months ago
Sell to soon ? After hours going to wild $$
👍️0
kbaz kbaz 3 months ago
Thank you for your participation.... looks fun for buyers....

👍️0
stock1ace1 stock1ace1 3 months ago
Squeeze it 2.00
👍️0
Invest-in-America Invest-in-America 3 months ago
ABVC: There was nothing substantive for them to WAIT upon, Dude!! As a PRIVATE firm, ABVC's affiliate's 'shares' had no value, per se. (I myself must now wait all day here to hopefully recoup most of my loses behind this conspicuous SCAM NEWS dumping company!!!)
👍️0
Invest-in-America Invest-in-America 3 months ago
ABVC: In TRUTH --- as I myself BELATEDLY 'reasoned-out" --- their (superficially epic) 'news' was merely concocted FLUFF!!! I.e., they cleverly received tons of CHEAP SHARES from a private firm --- which was going to toss them into a DUMPSTER anyway, next Tuesday!!!
👍️0
subslover subslover 3 months ago
Won't Get Fooled Again

👍️0
subslover subslover 3 months ago
Won't Get Fooled Again

👍️0
kbaz kbaz 3 months ago
The Gift that Keeps giving. What is next big news.... Merge into a Giant AI Pharma Company????? HAHAHAHAHAHAHAHA!!!!!! BUY SELL BUY SELL BUY SELL!!!! Rinse and repeat
👍️0
subslover subslover 3 months ago
You should give these clowns a call and ask them why. https://abvcpharma.com/
👍️0
kbaz kbaz 3 months ago
OK!!!! Whatever!?!?!? hahahhahahah Why don't they wait 'til $5's
👍️0
subslover subslover 3 months ago
The company is dumping new shares into buyers.
👍️0
kbaz kbaz 3 months ago
Showing Some strength in build for a Multi Day'er........ Stair Stepping to Higher!?!?!?!
👍️0
subslover subslover 3 months ago
All a game of Craps my friend.
👍️0
TheFinalCD TheFinalCD 3 months ago
or cit the bed... one or the other

LL
👍️0
subslover subslover 3 months ago
Excellent! Once the market opens this could blow its top!
👍️0
TheFinalCD TheFinalCD 3 months ago
$ABVC 2.01 DIP


FOR THE DIPCHITS
👍️0
subslover subslover 3 months ago
As of November 9, 2023, there were 7,231,940 shares of common stock, par value per share $0.001, issued and outstanding.
👍️0
subslover subslover 3 months ago
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc. ("AiBtl"), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. AiBtl is a private company, and the share value is based on the terms of the agreement between the parties and the valuation report done by an independent third party.

The Company entered into a definitive global licensing agreement with AiBtl on November 12, 2023, for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder). According to the terms of the agreement, AiBtl delivered 46M shares to the Company as the first milestone payment. The Company expects AiBtl to achieve the further milestones under the agreement, upon which the Company may receive the remaining licensing fees of up to $7M cash and 5% royalties of net sales, up to $200M.

"I am pleased with the progress of ABVC and AiBtl's collaborative work, which reflects ABVC's strength to grow and increase cash flow," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. He continued, "After this licensing payment, AiBtl becomes a subsidiary of ABVC, which holds 57% of the consolidated shares of AiBtl; accordingly, AiBtl is now also considered a related party.
“We believe this milestone payment marks the beginning of ABVC's revenue generation through licensing deals and opens new avenues that could potentially increase ABVC's revenue. AiBtl will help ABVC conduct international business development for the MDD and ADHD markets and bridge the partnership with international pharmaceutical companies."

"Completing out-licensing for the licensed products is our priority to strengthen our collaboration with ABVC," said AiBtl's Chief Executive Officer Russman Jaimes. He further commented, "AiBtl is a US company registered in Delaware. We are working on progressive joint ventures in Asia to expand the healthcare business and are poised to strengthen it. With ABVC's strong pipeline of products, we believe AiBtl has a strong future."

Management believes the Company's pipeline of products has excellent market potential. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032 with a CAGR of 2.8% over the forecast period[1]. According to the Polaris market research report, the global ADHD treatment market was valued at $15.23 billion in 2022 and is expected to grow at a CAGR of 7.3% over the forecast period between 2023-2032.[2] Straits Research reports that the global botanical drug market size was valued at $163 million in 2021 and is expected to be valued at $3.2 billion; the market is expected to grow at a CAGR of 39% during the forecast period (2022–2030).[3]

About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials for PMA (pre-Market Approval).

Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale wo
👍️0

Your Recent History

Delayed Upgrade Clock